Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Germany's formulary and hospital buyers just don't stop ordering at all. That's the single biggest reason Cefaclor sits where it does. A value of USD 286/KG in Q2 2026, up by 4.0% from USD 275/KG in Q1, the highest of all the tracked markets. The firm 7-ADCA and phenylglycine feedstock costs added a second layer of pressure on top of that steady demand. Globally, the prices moved from a value of USD 255.2/KG to USD 264.8/KG, a gain of 3.8 percent. Expect a range of USD 265-292/KG for the second half of 2026 (H2 2026). The respiratory infection treatment demand and firm feedstock costs both hold at their current pace.
Cefaclor is a second-generation cephalosporin antibiotic, made through a semi-synthetic modification of 7-ADCA, a fermentation-derived intermediate, followed by side-chain acylation and purification to a USP-grade purity. Compared to the first-generation cephalosporins, it offers a broader activity against gram-negative organisms while still holding onto a solid gram-positive coverage, part of why it's stayed a formulary staple. The respiratory tract infection treatment pulls the largest share of the demand, covering otitis media, bronchitis, and pharyngitis across oral capsules, tablets, and suspensions. The skin and urinary tract infection treatment follows next. The veterinary formulation use fills out the rest. The 7-ADCA and phenylglycine feedstock costs anchor the price. The fermentation capacity utilisation adds to that further. The seasonal respiratory prescription demand determines the timing of any given price move.
Sustained, not accelerating, a meaningful distinction for the picture heading into the second half of 2026 (H2 2026). The formulary and hospital buyers kept the procurement active through the H1, tracking a consistent respiratory infection treatment demand across every major market rather than any one region driving the pattern. The 7-ADCA and phenylglycine feedstock costs firmed steadily throughout. That alone explains most of the production floor's upward drift.
A 7-ADCA feedstock cost spike, or a disruption at a major fermentation facility, could push the prices above the band. A softer respiratory prescription demand, or new capacity coming online, would work the other way around.
| Region | 2026 Price Range (USD/KG) | Outlook |
| Global Average | 265 - 292 | Respiratory infection demand and feedstock cost support |
| United States | 277 - 305 | Compliance and formulary demand maintain firm pricing |
| China | 249 - 274 | Fermentation capacity keeps China most affordable |
| Germany | 286 - 315 | Steady formulary demand supports the highest premium |
| India | 260 - 286 | Export-oriented production supports firm middle |
The US prices rose by 3.7% to a value of USD 277/KG. The compliance and testing expenses kept the landed costs elevated all through the quarter. A steady formulary demand meant there was little room for that pressure to ease.
Why did the price of Cefaclor change in Q2 2026 in the United States?
Compliance and testing expenses kept landed import costs elevated throughout the quarter. Steady formulary and hospital demand for respiratory infection treatment supported buying regardless. Firm 7-ADCA feedstock costs added a further layer of pressure near USD 277/KG.
China rose by 3.8% to a value of USD 249/KG, still the cheapest tracked market. The fermentation capacity utilisation stayed firm throughout. A growing export demand pushed the market higher without any real supply strain.
Why did the price of Cefaclor change in Q2 2026 in China?
Fermentation capacity utilisation at 7-ADCA supplying facilities stayed firm all quarter. Growing export demand from formulators lifted procurement steadily. Domestic fermentation capacity kept China the most competitive source despite the increase.
Germany led every single tracked market at a value of USD 286/KG, up by 4.0%, the sharpest quarterly move of all four regions. The steady formulary and hospital demand explains most of it. The firm feedstock costs added a smaller contribution on top.
Why did the price of Cefaclor change in Q2 2026 in Germany?
Steady formulary and hospital procurement kept European buyers consistently active throughout the quarter. Firm 7-ADCA and phenylglycine feedstock costs elevated production expenses on top of that. USD 286/KG is where the quarter closed.
India climbed by 3.6% to a value of USD 260/KG. The export-oriented pharmaceutical demand kept growing steadily. The fermentation feedstock costs firmed alongside it, the same two-factor pattern that's been running for a while now.
Why did the price of Cefaclor change in Q2 2026 in India?
Export-oriented pharmaceutical demand kept building through the quarter. Fermentation feedstock costs firmed in line with broader input cost inflation. Domestic formulation demand added a bit more support near USD 260/KG.
The US prices rose by 4.3% to a value of USD 267/KG in Q1. Firm feedstock costs. Steady formulary demand. Both supported the increase, setting up the continued gain that followed in the Q2.
Why did the price of Cefaclor change in Q1 2026 in the United States?
Firm 7-ADCA feedstock costs raised production expenses steadily through the quarter. Steady formulary demand supported consistent buying alongside that. USD 267/KG is where things settled.
China's Q1 average rose by 4.3% to a value of USD 240/KG. The steady fermentation output and the growing export demand supported the gradual increase. A fairly typical quarter for this particular market.
Why did the price of Cefaclor change in Q1 2026 in China?
Steady fermentation output at key facilities supported consistent supply through the quarter. Growing export demand from formulators lifted procurement in step with that. The market advanced to USD 240/KG.
Germany rose by 4.2% to a value of USD 275/KG in Q1. Steady formulary demand. Firming feedstock costs. The same combination pushed things further in the Q2.
Why did the price of Cefaclor change in Q1 2026 in Germany?
Steady formulary and hospital procurement supported consistent buying through the quarter. Firming feedstock costs raised European production expenses alongside that. USD 275/KG is where the quarter closed.
India rose by 4.1% to a value of USD 251/KG in Q1. Growing export-oriented demand. Firming fermentation costs. Both set the stage for the stronger gain in the Q2.
Why did the price of Cefaclor change in Q1 2026 in India?
Demand from export-oriented pharmaceutical buyers stayed on an upward track all quarter. Firming fermentation feedstock costs pushed the production floor up alongside that. USD 251/KG is where things landed.
Every single quarter tracked closed higher than the one before it. A remarkably steady climb for a generic antibiotic, with the gains clustering tightly in the 3.8 to 4.2 percent range each time. From a value of USD 218.1/KG in Q1 2025 to USD 264.8/KG by Q2 2026, a cumulative gain of 21.4 percent. The 7-ADCA and phenylglycine feedstock cost cycles, along with the seasonal respiratory prescription demand alongside, explain nearly all of the sustained increase.
| Quarter | Price (USD/KG) | QoQ Change | Direction |
| Q2 2026 | 264.8 | +3.8% | ↑ Rising |
| Q1 2026 | 255.2 | +4.2% | ↑ Rising |
| Q4 2025 | 244.8 | +4.0% | ↑ Rising |
| Q3 2025 | 235.4 | +3.9% | ↑ Rising |
| Q2 2025 | 226.5 | +3.9% | ↑ Rising |
| Q1 2025 | 218.1 | - | - Stable |
Steady, quarter-over-quarter growth, that was the year 2025 for Cefaclor, with the feedstock costs doing most of the work. The global average opened at a value of USD 218.1/KG in Q1, closed at USD 244.8/KG in Q4, a gain of 12.2 percent. The firm 7-ADCA and phenylglycine feedstock costs, with a consistent formulary and hospital procurement alongside, drove the increase throughout. No single quarter stood out as unusual here.
The US prices rose by 12.3 percent, from a value of USD 228/KG to USD 256/KG. The compliance costs, along with a steady formulary demand, drove the sustained increase throughout the year.
The Chinese prices climbed by 12.2 percent, from a value of USD 205/KG to USD 230/KG. The steady fermentation output, along with a growing export demand, drove the sustained increase.
The German prices rose by 12.3 percent, from a value of USD 235/KG to USD 264/KG. A steady formulary and hospital demand drove the year-long climb across the entire European market.
The Indian prices advanced by 12.1 percent, from a value of USD 215/KG to USD 241/KG. A growing export-oriented pharmaceutical demand pushed the trend steadily higher throughout the year.
Expert Market Research: Your Source for Real-Time Cefaclor Price Intelligence
Expert Market Research tracks the Cefaclor prices continuously, across every major producing and consuming region. The team traces the causation through the 7-ADCA and phenylglycine feedstock economics, the fermentation capacity cycles, and the shifting respiratory infection treatment demand. Contact Expert Market Research today for the Cefaclor pricing data, a bespoke market analysis, and a strategic procurement advisory.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
The respiratory tract infection treatment accounts for the largest share of the demand, covering otitis media, bronchitis, and pharyngitis across oral capsules, tablets, and suspensions. The skin and urinary tract infection treatment, with the veterinary formulation use alongside, make up the rest.
The Q2 2026 prices come to a value of USD 277/KG in the United States, USD 249/KG in China, USD 286/KG in Germany, and USD 260/KG in India. A steady formulary demand keeps Germany at the top of the range.
The global average rose from a value of USD 244.8/KG in Q4 2025 to USD 255.2/KG in Q1 2026, then to USD 264.8/KG by Q2, a gain of 3.8 percent across the half-year. The firm feedstock costs, along with a sustained formulary demand, drove the increase, extending a pattern that's held steady for over a year now.
The firm 7-ADCA and phenylglycine feedstock costs have kept the production expenses elevated across the major producing regions for several quarters running. A steady formulary and hospital demand for the respiratory infection treatment has supported a consistent buying throughout. The compliance and testing expenses have added further cost pressure specifically in developed markets like the US and Germany.
A range of USD 265 to 292/KG looks like the right one for the rest of the year 2026, assuming the respiratory infection treatment demand and the current feedstock costs both hold steady.
Germany carries the highest cost, owing to a steady formulary demand. The United States holds a premium tied to the compliance costs. India sits in the middle, owing to the export-oriented production. China prices the lowest, thanks to a substantial fermentation capacity.
Monthly. Reach out to the Expert Market Research team directly for real-time pricing intelligence.
The 7-ADCA and phenylglycine feedstock costs sit at the core of it, with the fermentation capacity utilisation close behind. The seasonal respiratory prescription demand cycles matter too, and the compliance or testing expenses can shift the regional pricing at the margin.
China and India lead on a substantial fermentation and semi-synthetic processing capacity, with the European producers maintaining a strong presence in the formulary-grade supply. A shift in the 7-ADCA feedstock costs tends to ripple across every single regional market within a quarter or so.
Timing the formulary and hospital contracts around the seasonal respiratory prescription cycles is worth the effort here. The 7-ADCA feedstock costs give the clearest signal for the production floor, and given how sustained the upward momentum has been, locking in a forward coverage early tends to pay off.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.